Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Provided By GlobeNewswire
Last update: Nov 8, 2024
Two oral presentations and multiple posters on clinical and
preclinical-stage candidates to be presented at SITC, demonstrating
the strength of Immatics’ TCR-T PRAME franchise to target solid cancers
